CoChat

Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance

Published version of a preprint

The DOI matches its Crossref record; 49 of the 55 references it cites were found in a registry or an index.

Abstract

DNA-damaging anticancer drugs remain a part of metastatic melanoma therapy. Epigenetic reprogramming caused by increased histone deacetylase (HDAC) activity arising during tumor formation may contribute to resistance of melanomas to the alkylating drugs temozolomide, dacarbazine, and fotemustine. Here, we report on the impact of class I HDACs on the response of malignant melanoma cells treated with alkylating agents. The data show that malignant melanomas in situ contain a high level of HDAC1/2 and malignant melanoma cells overexpress HDAC1/2/3 compared with noncancer cells. Furthermore, pharmacologic inhibition of class I HDACs sensitizes malignant melanoma cells to apoptosis following exposure to alkylating agents, while not affecting primary melanocytes. Inhibition of HDAC1/2/3 caused sensitization of melanoma cells to temozolomide in vitro and in melanoma xenografts in vivo. HDAC1/2/3 inhibition resulted in suppression of DNA double-strand break (DSB) repair by homologous recombination because of downregulation of RAD51 and FANCD2. This sensitized cells to the cytotoxic DNA lesion O6-methylguanine and caused a synthetic lethal interaction with the PARP-1 inhibitor olaparib. Furthermore, knockdown experiments identified HDAC2 as being responsible for the regulation of RAD51. The influence of class I HDACs on DSB repair by homologous recombination and the possible clinical implication on malignant melanoma therapy with temozolomide and other alkylating drugs suggests a combination approach where class I HDAC inhibitors such as valproic acid or MS-275 (entinostat) appear to counteract HDAC- and RAD51/FANCD2-mediated melanoma cell resistance. Cancer Res; 76(10); 3067–77. ©2016 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2680

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 92

Metadata

Authors
Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P.
Affiliations
Johannes Gutenberg University Mainz (DE)
Venue
Cancer Research
Published
2016-05-12
Volume
76
Issue
10
Pages
3067-3077
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2298649194
Cited by
91
References
55
Citations by year
2026: 5 · 2025: 8 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 14 · 2019: 6 · 2018: 12 · 2017: 9 · 2016: 6
FWCI
5.72
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
German Research Foundation (RO3617)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
histone deacetylase, class I HDACs, HDAC1, HDAC2, HDAC3, melanoma, drug resistance, temozolomide, alkylating agents, RAD51, FANCD2, homologous recombination, DNA double-strand break repair, O6-methylguanine, synthetic lethality, PARP-1 inhibitors, olaparib, valproic acid, entinostat, epigenetic reprogramming, apoptosis
MeSH terms
Cutaneous Malignant Melanoma, Animals, DNA Repair, Fluorescent Antibody Technique, Histone Deacetylases, Humans, Immunoenzyme Techniques, Melanoma, RNA, Messenger, Skin, Skin Neoplasms, Tumor Cells, Cultured, Blotting, Western, Mice, SCID, Mice, Inbred NOD, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Cell Proliferation, Rad51 Recombinase, Mice, Fanconi Anemia Complementation Group D2 Protein, DNA Breaks, Double-Stranded, Histone Deacetylase Inhibitors, Homologous Recombination, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2680
The paper
Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016). Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.